By Manufacturing Process

Recombinant / Biologic Market Analysis

Cross-industry research covering Recombinant / Biologic across 1 market reportspanning Pharmaceuticals.

1 Reports

1 Industries

Reports Covering Recombinant / Biologic

Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR

Pharmaceuticals·Market: USD 25.3 Billion (2025)·CAGR: 6.4%

Bezlotoxumab and pipeline anti-infective monoclonals require mammalian cell culture or microbial expression systems with BLA-grade process validation. CMO/CDMO capacity constraints for bioreactor suites remain a bottleneck for mid-stage anti-infective biologic pipeline candidates, a supply-side constraint that limits how rapidly biosimilar-adjacent competition can develop in this sub-segment.

15%

Market Share

8.0%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments